Home > Resources > Company Profiles > AstraZeneca PLC

AstraZeneca PLC (AZN)

Your Name

Your Email Address *
Send a copy to me

Recipient's Email Address *

Separate multiple email addresses (max 20) with commas.

Subject *

Message

0/1500

Enter the text you see in the image *

Letters are not case-sensitive, disregard spaces.

Try a New One

This helps us prevent automated registrations and spamming.

Email Confirmation

David R. Brennan , CEO/Director

www.astrazeneca.com

Industry: Healthcare

OPEN

LAST

PREV CLOSE

CHANGE

VOLUME

Overview

News

People

Financials

Overview

A pharmaceutical company, which provides a range of medicines designed to fight disease in important areas of healthcare.

Portfolio Articles

AstraZeneca Scoops up MedImmune
British pharmaceutical giant AstraZeneca pays a premium for MedImmune, banking on its flu and respiratory drugs.

Apr 23 2007

See more news on this company

News Feeds

Astra seeks approval for diabetes drug AP
Jul 23 2008
Infinity shares dip on canceled program AP
Jul 15 2008
New pharma ethics rules eliminate gifts and meals AP
Jul 11 2008
Sector Snap: Diabetes drug developers AP
Jul 03 2008
Teva loses patent dispute, plans appeal AP
Jul 01 2008
Former MedImmune chief David Mott to leave AstraZeneca Baltimore
Jun 27 2008

Press Releases

Bristol-Myers Squibb and AstraZeneca Submit New Drug Application in the United States and Marketing Authorization Application in Europe for ONGLYZA(TM) (saxagliptin) for the Treatment of Type 2 Diabetes Jul-23-2008, 08:00AM EDT
AstraZeneca Survey: Healthcare Professionals Leading Source of Information on Company's Prescription Savings Programs Jul-23-2008, 08:00AM EDT
AstraZeneca Supports New PhRMA Code on Interactions with Healthcare Providers: Will Ensure Compliance to Benefit Patient Care Jul-10-2008, 07:45AM EDT
Cubist Pharmaceuticals to Promote in the U.S. AstraZeneca's Broad Spectrum Antibiotic, MERREM I.V. Jul-02-2008, 06:30AM EDT
Zacks Bull and Bear of the Day Highlights: Vivo Participacoes, Werner Enterprises, AstraZeneca, Raytheon and Primedia Jun-24-2008, 06:00AM EDT

News From Around the Web

News

In print: Stories in today's print and e-edition July 24 (Marshall Democrat-News)

Jul 24 2008
After success at R&B, Regina Belle turns to gospel (AOL News)

Jul 24 2008
After success at R&B, Regina Belle turns to gospel: 'it's a huge difference' (Maclean's)

Jul 24 2008
Arthur Allen on "A Passion for Tomatoes" (Smithsonian)

Jul 24 2008
• UW football: Badgers fans beware, I'm an AP voter again (Wisconsin State Journal)

Jul 24 2008
July 3, 2008 -- Study Says Many ... (Advance for Health Information Executives)

Jul 23 2008
AP NEWS ALERT: We Just Got Interesting (AOL News)

Jul 23 2008

Blogs

Boehlert: The AP has a Ron Fournier problem (Media Matters for America)

Jul 22 2008
College Football Hall of Fame (Campus Confidential)

Jul 22 2008
AP: Maliki playing domestic politics (Inside L.I. Politics - Spin Cycle)

Jul 21 2008
AP Headline: 'Is Media Playing Fair In Campaign Coverage?' (NewsBusters)

Jul 20 2008
O'Reilly: 'AP May Now Be Dead As an Objective News Organization' (NewsBusters)

Jul 19 2008

Employees

Number of Employees: 67,900

Revenue per Employee: $428,574

Top Executives

Jan Lundberg, Executive VP, Divisional

David Smith, Executive VP, Divisional

David Mott, CEO, Subsidiary/President, Subsidiary

Simon Lowth, CFO/Director

Bruno Angelici, Executive VP, Geographical

Lynn Tetrault, Executive VP, Divisional

Tony Zook, CEO, Geographical/Executive VP, Divisional/President, Geographical

Board of Directors

Michele J. Hooper, Director

Joseph Jimenez, Director

Simon Lowth, CFO/Director

Hakan Mogren, KBE, Deputy Chairman/Director

Louis Schweitzer, Chairman of the Board/Director

John Silvester Varley, Director

Jane Henney, Director

Bo Angelin, Director

John Buchanan, Director

Sir Peter Leahy Bonfield, Director

John Patterson, CBE, FRCP, Director

Marcus Wallenberg, Director

Professor Dame Nancy Rothwell, Director

Graeme Musker, Secretary

Dame Bridget Ogilvie, Director

Jonathan R Symonds, CBE, CFO/Director

Financials

Quarterly

Annual

Income Statement	05/2008	02/2008	11/2007	08/2007
Sales	800 Mil.	1.27 Bil.	879 Mil.	1.3 Bil.
Gross Operating Profit	6.88 Bil.	6.9 Bil.	6.27 Bil.	5.97 Bil.
Operating Income before D & A (EBITDA)	2.84 Bil.	2.35 Bil.	2.39 Bil.	2.08 Bil.
Total Income Before Interest Expenses (EBIT)	2.52 Bil.	2.18 Bil.	2.24 Bil.	2.21 Bil.
Total Net Income	1.5 Bil.	1.27 Bil.	1.34 Bil.	1.43 Bil.
Basic EPS, Total	1.03	0.86	0.91	0.95
Diluted EPS, Total	1.03	0.86	0.9	0.95

BALANCE STATEMENT	05/2008	02/2008	11/2007	08/2007
Cash and Equivalents	2.92 Bil.	5.87 Bil.	3.43 Bil.	4.95 Bil.
Total Assets	14.69 Bil.	17.08 Bil.	14.69 Bil.	16.08 Bil.
Total Liabilities	15.68 Bil.	15.19 Bil.	15.53 Bil.	24.93 Bil.
Total Capitalization	25.84 Bil.	26.03 Bil.	23.61 Bil.	15.9 Bil.

Cash Flow	05/2008	02/2008	11/2007	08/2007
Net Cash From Continuing Operations	2.39 Bil.	7.51 Bil.	4.51 Bil.	3.18 Bil.
Net Cash From Investing Activities	-2.94 Bil.	-14.89 Bil.	-14.46 Bil.	-14.49 Bil.
Net Cash From Financing Activities	-2.38 Bil.	6.05 Bil.	6.25 Bil.	9.16 Bil.
Net Change in Cash & Cash Equivalents	-2.93 Bil.	-1.26 Bil.	-3.64 Bil.	-2.12 Bil.

Income Statement	2008	2007	2006	2005
Sales	4.56 Bil.	4.21 Bil.	4.03 Bil.	3.88 Bil.
Gross Operating Profit	25 Bil.	22.26 Bil.	19.92 Bil.	17.54 Bil.
Operating Income before D & A (EBITDA)	9.22 Bil.	9.04 Bil.	7.64 Bil.	5.72 Bil.
Total Income Before Interest Expenses (EBIT)	9.05 Bil.	9.09 Bil.	7.17 Bil.	4.91 Bil.
Total Net Income	5.6 Bil.	6.04 Bil.	4.71 Bil.	3.81 Bil.
Basic EPS, Total	3.74	3.86	2.91	2.28
Diluted EPS, Total	3.73	3.85	2.91	2.28

BALANCE STATEMENT	2008	2007	2006	2005
Cash and Equivalents	5.87 Bil.	7.1 Bil.	545 Mil.	1.06 Bil.
Total Assets	17.08 Bil.	16.94 Bil.	13.77 Bil.	14.44 Bil.
Total Liabilities	15.19 Bil.	9.45 Bil.	6.84 Bil.	7.78 Bil.
Total Capitalization	26.03 Bil.	16.39 Bil.	14.71 Bil.	15.45 Bil.

Cash Flow	2008	2007	2006	2005
Net Cash From Continuing Operations	7.51 Bil.	7.69 Bil.	6.74 Bil.	4.87 Bil.
Net Cash From Investing Activities	-14.89 Bil.	-272 Mil.	-1.18 Bil.	-941 Mil.
Net Cash From Financing Activities	6.05 Bil.	-5.37 Bil.	-4.57 Bil.	-3.62 Bil.
Net Change in Cash & Cash Equivalents	-1.26 Bil.	2.09 Bil.	968 Mil.	309 Mil.

AstraZeneca PLC (AZN)

Company Information

Overview

Employees

Top Executives

Board of Directors

Financials

Company Profile Change Request